EarningsQ2 2026 Earnings Report
DE:EVL Q2 2026 EPS Results
Actual EPS<€0.01
Consensus EPS-€0.03
Beat/MissBeat by +€0.04
One Year Ago EPS-€0.22
DE:EVL Q2 2026 Revenue Results
Actual Revenue€74.89M
Expected Revenue€72.63M
Beat/MissBeat by +€2.26M
YoY Revenue Growth+21.18%
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeAfter Close
Conference CallWednesday, August 5, 2026
DE:EVL Upcoming Earnings
Evolus's next earnings date is estimated for November 10, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:EVL Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated clear operational momentum: double-digit top-line growth (21% in Q2, 14% year-to-date), third consecutive quarter of positive adjusted EBITDA, expanded international presence, new strategic licensing (ProFuelo) and an upwardly revised full-year revenue and margin outlook. These positives were tempered by sequential increases in operating expenses, modest absolute adjusted EBITDA, a decline in cash versus the prior quarter and ongoing tariff uncertainty that requires inventory repositioning. Given the company’s raised guidance, profitable growth trajectory, and strategic partnerships that expand the product portfolio, the highlights materially outweigh the lowlights.Company Guidance
Strong Q2 Revenue Growth
Global net revenue of $84.1 million in Q2, up 21% year-over-year, driven by diversified portfolio performance.
Toxin and HA Revenue Contribution
Global toxin revenue of $75.2 million and injectable hyaluronic acid gel revenue of $8.9 million, with toxin business driving the bulk of Q2 sales.
Positive Adjusted EBITDA Momentum
Third consecutive quarter of positive adjusted EBITDA at $4.7 million; adjusted EBITDA improved by $12.6 million year-over-year.
Raised Full-Year Guidance and Margin Outlook
Raised the lower end of 2026 revenue guidance to $330 million (range $330M–$337M, midpoint $333.5M). Increased full-year adjusted gross profit margin guidance to 67.0%–67.5%.
Year-to-Date Growth and Operating Leverage
First half 2026 revenue up 14% year-over-year, exceeding prior guidance pace and cited as basis for updated outlook; management highlighted operating leverage as additional products scale.
Portfolio Expansion and Commercial Traction
Evolysse revenue rose by more than $2 million sequentially; Jeuveau showing strengthening customer loyalty and market share gains; accounts buying both Jeuveau and Evolysse purchase ~2.5x more volume than single-product accounts; portfolio growth bundle achieved ~70% Evolysse penetration among participating customers vs ~25% across overall customer base.
International Expansion & Product Launches
Launched the Estyme hyaluronic acid collection in Europe and expanded Symatese partnership into Canada, Australia and New Zealand; management expects Evolysse and international business each to contribute >10% of company revenue in 2026.
Strategic Licensing Deal for Skin Quality (ProFuelo)
Exclusive U.S. licensing partnership with IPSY to develop and commercialize ProFuelo (skin quality injectable); management projects potential >$100 million peak annual revenue for the asset and expects PMA approval timeline around 2030; Evolus will lead U.S. regulatory and commercialization.
Healthy Gross Margins and Tariff Benefit
Reported gross margin of 68% and adjusted gross margin of 69% in Q2; gross margin benefited ~120 basis points from a tariff refund recognized during the quarter.
Balance Sheet Flexibility
Ended Q2 with $45.2 million in cash equivalents, access to $100 million additional liquidity under the Pharmacon facility and capacity under the revolving credit facility; management states company is funded to profitability and does not anticipate additional equity financing.
DE:EVL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed